Please assess the completion status of the following clinical trial:

Trial Title: Intravitreal Dexamethasone Implant for Persistent Macular Thickening and Edema After Vitrectomy for Epiretinal Membrane

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient of the Wills Eye Institute Retina service, including all Mid-Atlantic Retina offices~2. Volunteer patients age 18 years and older~3. Healthy enough to participate in the study~4. Willing and able to consent to participation in the study~5. History of pars plan vitrectomy for symptomatic epiretinal membrane at least 3 months prior to study enrollment date~6. BCVA of 20/40 or worse~7. CMT of at least 400 micrometers with or without cystoid macular edema on SD-OCT~8. Prior treatment with topical NSAIDs without resolution of macular thickening or visual acuity improvement~Exclusion Criteria:~1. Advanced glaucoma (cup-disc ratio of 0.8 or greater)~2. History of glaucoma filtering or tube shunt implant surgery~3. Steroid responsive intraocular hypertension~4. Diabetic retinopathy~5. History of uveitis~6. Use of systemic or intraocular corticosteroids~7. Active or suspected ocular or periocular infections~8. Other confounding intraocular pathology

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: t

Study Arms:
- 0.7mg dexamethasone intravitreal implant (Type: EXPERIMENTAL): Single intravitreal implantation of 0.7mg dexamethasone with a six month follow up period

Based on this trial design, predict the completion outcome and termination type (if applicable).